Privia Health Group (NASDAQ:PRVA) Stock Rating Upgraded by Zacks Research

Privia Health Group (NASDAQ:PRVA) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on PRVA. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research note on Thursday, July 23rd. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Barclays lowered their price target on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Evercore set a $26.00 price target on shares of Privia Health Group in a research report on Wednesday, April 8th. Finally, Canaccord Genuity Group reduced their price objective on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Privia Health Group has a consensus rating of “Moderate Buy” and an average target price of $31.15.

Privia Health Group Price Performance

Shares of NASDAQ PRVA opened at $22.00 on Wednesday. Privia Health Group has a one year low of $19.08 and a one year high of $28.82. The firm’s 50 day simple moving average is $24.61 and its two-hundred day simple moving average is $23.35. The stock has a market capitalization of $2.77 billion, a P/E ratio of 137.51, a PEG ratio of 1.90 and a beta of 0.85.

Insider Activity at Privia Health Group

In other Privia Health Group news, CEO Parth Mehrotra sold 15,647 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $22.64, for a total transaction of $354,248.08. Following the completion of the sale, the chief executive officer owned 434,357 shares of the company’s stock, valued at $9,833,842.48. This represents a 3.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO David Mountcastle sold 21,275 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $27.67, for a total transaction of $588,679.25. Following the completion of the sale, the chief financial officer directly owned 164,853 shares in the company, valued at approximately $4,561,482.51. This trade represents a 11.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 452,357 shares of company stock worth $11,436,655 in the last three months. 5.70% of the stock is owned by insiders.

Institutional Trading of Privia Health Group

Several large investors have recently modified their holdings of the business. Royal Bank of Canada raised its position in Privia Health Group by 63.5% during the 1st quarter. Royal Bank of Canada now owns 245,633 shares of the company’s stock valued at $5,514,000 after purchasing an additional 95,371 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Privia Health Group by 24.7% during the first quarter. AQR Capital Management LLC now owns 40,781 shares of the company’s stock valued at $916,000 after buying an additional 8,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Privia Health Group by 3.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 118,764 shares of the company’s stock valued at $2,666,000 after buying an additional 3,714 shares during the period. Intech Investment Management LLC raised its holdings in shares of Privia Health Group by 55.1% during the first quarter. Intech Investment Management LLC now owns 56,553 shares of the company’s stock valued at $1,270,000 after acquiring an additional 20,082 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Privia Health Group during the first quarter valued at approximately $154,000. 94.48% of the stock is owned by institutional investors.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Raised 2026 outlook: Management increased full-year guidance for attributed lives to 1.625–1.650 million, practice collections to the high end of $3.65–$3.75 billion, GAAP revenue to the high end of $2.35–$2.45 billion, and adjusted EBITDA to $145–$155 million. It also expects approximately 70%–80% of adjusted EBITDA to convert to free cash flow. Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
• Positive Sentiment: Strong quarterly growth: Q2 revenue rose 21.4% year over year to $632.6 million, exceeding the $597.3 million consensus. Adjusted EPS was $0.19 versus the $0.07 analyst estimate, while net income increased to $9.0 million from $2.7 million. Privia Health Q2 Earnings Report
• Positive Sentiment: Operating momentum improved: Implemented providers grew 10.1% to 5,644, value-based-care attributed lives increased 19.2% to 1.647 million, and adjusted EBITDA climbed 29.1% to $37.4 million. Adjusted EBITDA margin expanded to 28.3% from 25.2%.
• Neutral Sentiment: Analyst comparisons are complicated by differing definitions: GAAP diluted EPS was $0.07, while adjusted EPS was $0.19. The adjusted figure benefited from add-backs, including $19.4 million of non-cash stock compensation expense.
• Negative Sentiment: Cash-flow concerns: Privia used $48.4 million in operating cash during the first half, largely because accounts receivable increased by $172.4 million. Cash declined to $412.2 million from $479.7 million at year-end.
• Negative Sentiment: PRVA’s valuation remains demanding, with a reported price-to-earnings ratio near 150. Heavy insider selling cited in recent data may also weigh on sentiment, even though the company’s operating results and outlook improved.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.